keyword
MENU ▼
Read by QxMD icon Read
search

Dyslipidaemia

keyword
https://www.readbyqxmd.com/read/28219783/are-we-reducing-the-risk-of-cardiovascular-disease-and-improving-the-quality-of-life-through-preventive-health-care-results-of-a-population-based-study-in-south-australia
#1
David Alejandro González-Chica, Eleonora Dal Grande, Jacqueline Bowden, Michael Musker, Phillipa Hay, Nigel Stocks
This study investigated the achievement of lifestyle recommendations and use of preventive medication in people who 1) are obese, 2) or have metabolic risk factors (hypertension, dyslipidaemia, and/or diabetes), 3) or have cardiovascular disease (CVD), 4) or are healthy, and the impact this preventive health care had on their 'Health-Related Quality of Life' (HRQoL). Cross-sectional survey conducted in 2015 with 2379 South Australian adults (57.1±14years; 51.7% females). Physical (PCS) and mental components scores (MCS) of HRQoL were assessed using the SF-12 questionnaire...
February 17, 2017: Preventive Medicine
https://www.readbyqxmd.com/read/28218263/non-alcoholic-fatty-liver-disease-an-emerging-driving-force-in-chronic-kidney-disease
#2
REVIEW
Giovanni Targher, Christopher D Byrne
Non-alcoholic fatty liver disease (NAFLD) is caused by an accumulation of fat in the liver; the condition can progress over time to increase the risk of developing cirrhosis, end-stage liver disease and hepatocellular carcinoma. The prevalence of NAFLD is increasing rapidly owing to the global epidemics of obesity and type 2 diabetes mellitus (T2DM), and NAFLD has been predicted to become the most important indication for liver transplantation over the next decade. It is now increasingly clear that NAFLD not only affects the liver but can also increase the risk of developing extra-hepatic diseases, including T2DM, cardiovascular disease and chronic kidney disease (CKD), which have a considerable impact on health-care resources...
February 20, 2017: Nature Reviews. Nephrology
https://www.readbyqxmd.com/read/28209604/birth-size-risk-factors-across-life-and-cognition-in-late-life-protocol-of-prospective-longitudinal-follow-up-of-the-mynah-mysore-studies-of-natal-effects-on-ageing-and-health-cohort
#3
Murali Krishna, G Mohan Kumar, S R Veena, G V Krishnaveni, Kalyanaraman Kumaran, Samuel Christaprasad Karat, Patsy Coakley, Clive Osmond, John R M Copeland, Giriraj Chandak, Dattatray Bhat, Mathew Varghese, Martin Prince, Caroline Fall
INTRODUCTION: For late-life neurocognitive disorders, as for other late-life chronic diseases, much recent interest has focused on the possible relevance of Developmental Origins of Health and Disease (DOHaD). Programming by undernutrition in utero, followed by overnutrition in adult life may lead to an increased risk, possibly mediated through cardiovascular and metabolic pathways. This study will specifically examine, if lower birth weight is associated with poorer cognitive functioning in late life in a south Indian population...
February 16, 2017: BMJ Open
https://www.readbyqxmd.com/read/28206728/laparoscopic-roux-en-y-gastric-bypass-vs-laparoscopic-sleeve-gastrectomy-for-morbid-obesity-a-systematic-review-and-meta-analysis-of-lipid-effects-at-one-year-post-surgery
#4
Elisenda Climent, David Benaiges, Juan Pedro-Botet, Albert Goday, Ivan Solà, José M Ramón, Juana A Flores-LE Roux, Miguel Á Checa
INTRODUCTION: Results of the effects of Roux-en-Y gastric bypass (GB) and sleeve gastrectomy (SG) on triglyceride and high-density lipoprotein (HDL) cholesterol levels are controversial. Moreover, previous meta-analyses focused on global dyslipidaemia remission, but did not include the separate remission rates of the different lipid fractions. Hence, the aim of the present meta-analysis was to compare the outcomes (concentration change and remission rates) of GB and SG on diverse lipid disorders one year post-bariatric surgery (BS)...
February 15, 2017: Minerva Endocrinologica
https://www.readbyqxmd.com/read/28205202/polish-forum-for-prevention-guidelines-on-dyslipidaemia-update-2016
#5
Barbara Cybulska, Wiktor B Szostak, Krzysztof J Filipiak, Grzegorz Kopeć, Wojciech Drygas, Longina Kłosiewicz-Latoszek, Klaudia Knap, Andrzej Pająk, Jakub Podolec, Tomasz Zdrojewski, Danuta Czarnecka, Piotr Jankowski, Maciej Małecki, Grażyna Nowicka, Jerzy Stańczyk, Agnieszka Sarnecka, Anna Członkowska, Maciej Niewada, Anetta Undas, Adam Windak, Piotr Hoffman, Piotr Podolec
No abstract text is available yet for this article.
2017: Kardiologia Polska
https://www.readbyqxmd.com/read/28196738/cholesterol-levels-of-japanese-dyslipidaemic-patients-with-various-comorbidities-biobank-japan
#6
Hiroshi Yokomichi, Hokuto Noda, Akiko Nagai, Makoto Hirata, Akiko Tamakoshi, Yoichiro Kamatani, Yutaka Kiyohara, Koichi Matsuda, Kaori Muto, Toshiharu Ninomiya, Michiaki Kubo, Yusuke Nakamura, Zentaro Yamagata
BACKGROUND: Controlling serum cholesterol is critical to prevent cardiovascular disease in patients with dyslipidaemia. Guidelines emphasise the need to select treatment for dyslipidaemia based on specific patient profiles; however, there is little information about the serum cholesterol levels of patients in each profile in Japan. Therefore, we aimed to describe the serum cholesterol levels and prevalence of uncontrolled cases in Japanese patients with dyslipidaemia. METHODS: We included data for patients with dyslipidaemia between 2003 and 2007 from the BioBank Japan Project (66 hospitals)...
February 11, 2017: Journal of Epidemiology
https://www.readbyqxmd.com/read/28195199/pemafibrate-a-novel-selective-peroxisome-proliferator-activated-receptor-alpha-modulator-improves-the-pathogenesis-in-a-rodent-model-of-nonalcoholic-steatohepatitis
#7
Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Koji Fujita, Masato Yoneda, Toshiaki Takizawa, Satoru Saito, Yoji Nagashima, Atsushi Nakajima
The efficacy of peroxisome proliferator-activated receptor α-agonists (e.g., fibrates) against nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in humans is not known. Pemafibrate is a novel selective peroxisome proliferator-activated receptor α modulator that can maximize the beneficial effects and minimize the adverse effects of fibrates used currently. In a phase-2 study, pemafibrate was shown to improve liver dysfunction in patients with dyslipidaemia. In the present study, we first investigated the effect of pemafibrate on rodent models of NASH...
February 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28188508/potentially-inappropriate-prescribing-and-associated-factors-in-elderly-patients-at-hospital-discharge-in-brazil-a-cross-sectional-study
#8
Ana Luiza Pereira Moreira Mori, Renata Cunha Carvalho, Patricia Melo Aguiar, Maria Goretti Farias de Lima, Magali da Silva Pacheco Nobre Rossi, José Fernando Salvador Carrillo, Egídio Lima Dórea, Sílvia Storpirtis
Background The Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert doctors to Right Treatment (STOPP/START) criteria is used to identify instances of potentially inappropriate prescribing in a patient's medication regimen. Objective To determine the prevalence and predictors of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) among elderly patients at hospital discharge. Setting A university hospital medical clinic in Brazil. Method Discharge prescriptions were examined using the STOPP/START criteria...
February 10, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/28185675/-consensus-document-on-the-management-of-the-atherogenic-dyslipidaemia-of-the-spanish-society-of-arteriosclerosis
#9
Juan F Ascaso, Jesús Millán, Antonio Hernández-Mijares, Mariano Blasco, Ángel Brea, Ángel Díaz, Teresa Mantilla, Juan Pedro-Botet, Xavier Pintó
Positioning document and summary of recommendations recently published by the Working Group on Atherogenic Dyslipemia of the Spanish Society of Arteriosclerosis and by the European Society of Arteriosclerosis.
February 6, 2017: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/28185575/integration-of-metabolomics-lipidomics-and-clinical-data-using-a-machine-learning-method
#10
Animesh Acharjee, Zsuzsanna Ament, James A West, Elizabeth Stanley, Julian L Griffin
BACKGROUND: The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivotal role in lipid and carbohydrate metabolism and have been highlighted as potential treatments for obesity. This realisation started a search for NR agonists in order to understand and successfully treat MetS and associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesity and cardiovascular disease...
November 22, 2016: BMC Bioinformatics
https://www.readbyqxmd.com/read/28182622/non-alcoholic-fatty-liver-disease-and-hiv-adis-a-new-way-of-modulation-of-cardiovascular-risk
#11
Mohamed H Ahmed, Nazik Elmalaika Hussian, Akif Malik, Clare Woodward, Dushyant Mital
With the advent and subsequent success of antiretroviral therapy, human immunodeficiency virus (HIV) infection has largely become a chronic condition and is increasingly seen alongside metabolic disorders such as dyslipidaemia and insulin resistance. Furthermore, the administration of antiretroviral therapy (ART) itself is associated with an increase in the incidence of metabolic risk factors (namely insulin resistance, lipoatrophy, dyslipidaemia, and abnormalities of fat distribution in HIV patients). Thus, further challenges in the management of HIV patients include the management of diabetes and the metabolic syndrome, non-alcoholic fatty liver disease (NAFLD)...
February 9, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28181106/risk-factor-control-in-secondary-prevention-of-cardiovascular-disease-results-from-the-multi-ethnic-helius-study
#12
M Minneboo, S Lachman, M B Snijder, J T Vehmeijer, H T Jørstad, R J G Peters
OBJECTIVE: To evaluate the quality of contemporary secondary prevention of cardiovascular disease (CVD), and the differences between six ethnic groups in a large, observational cohort. DESIGN: We included participants with a self-reported history of CVD from the HEalthy LIfe in an Urban Setting (HELIUS) study, which investigates inequalities in health between six ethnic groups living in Amsterdam, the Netherlands. We quantified the proportions of patients who were at the preventive treatment goal according to the guidelines of the European Society of Cardiology for six risk factors: hypertension, dyslipidaemia, smoking, overweight, physical inactivity and diabetes mellitus, and the use preventive medication...
February 8, 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28174212/drug-eluting-stents-versus-bare-metal-stents-in-acute-myocardial-infarction-with-cardiogenic-shock
#13
Jakob Ledwoch, Georg Fuernau, Steffen Desch, Ingo Eitel, Christian Jung, Suzanne de Waha, Janine Poess, Steffen Schneider, Gerhard Schuler, Karl Werdan, Uwe Zeymer, Holger Thiele
OBJECTIVES: The aim of the present study was to assess the outcome of patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) receiving drug-eluting stents (DES) compared with bare-metal stents (BMS). Data comparing these two stent technologies in AMI with CS were limited. METHODS: A total of 783 patients with AMI and CS undergoing early revascularisation were included in the randomised Intra-aortic Balloon Pump in Cardiogenic Shock II trial (n=600) and the associated registry (n=183)...
February 7, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28155609/pathophysiology-of-diabetic-dyslipidaemia
#14
Theodosios Filippatos, Vasilios Tsimihodimos, Eleni Pappa, Moses Elisaf
Patients with diabetes usually exhibit diabetic dyslipidaemia. The aim of the review is to present the quantitative and qualitative alterations of lipids and lipoproteins and the associated mechanisms in patients with diabetic dyslipidaemia. The main quantitative changes observed in patients with diabetic dyslipidaemia are increased triglycerides and decreased high-density lipoprotein (HDL) cholesterol levels. Qualitative abnormalities mainly include increased small dense low-density lipoprotein particles (despite similar serum low-density lipoprotein cholesterol levels as non-diabetic subjects) and alterations in the apolipoprotein content of HDL particles...
January 31, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28155315/awareness-of-diabetic-foot-disease-amongst-patients-with-type-2-diabetes-mellitus-attending-the-chronic-outpatients-department-at-a-regional-hospital-in-durban-south-africa
#15
Thea T Goie, Mergan Naidoo
BACKGROUND: Diabetic foot disease (DFD) is a major challenge for the healthcare system, with enormous economic consequences for people living with diabetes, their families, and society, affecting both quality of life and quality of care. The study aim was to assess the level of awareness of DFD amongst patients with type 2 diabetes mellitus (T2DM). METHODS: An observational descriptive cross-sectional study was conducted at the chronic outpatients department of a regional hospital in Durban, South Africa...
November 17, 2016: African Journal of Primary Health Care & Family Medicine
https://www.readbyqxmd.com/read/28153452/adenosine-receptors-modulators-of-lipid-availability-that-are-controlled-by-lipid-levels
#16
REVIEW
Andrea Leiva, Enrique Guzmán-Gutiérrez, Susana Contreras-Duarte, Bárbara Fuenzalida, Claudette Cantin, Lorena Carvajal, Rocío Salsoso, Jaime Gutiérrez, Fabián Pardo, Luis Sobrevia
Adenosine as well as agonists and antagonists for the four adenosine receptor subtypes (A1R, A2AR, A2BR and A3R) play a role in several key physiological and pathophysiological processes, including the regulation of vascular tone, thrombosis, immune response, inflammation, and angiogenesis. This review focuses on the adenosine-mediated regulation of lipid availability in the cell and in the systemic circulation as well in humans and animal models. Therefore, adenosine, mainly by acting on A1R, inhibits lipolysis activity, leading to reduction of the circulating fatty acid levels...
January 30, 2017: Molecular Aspects of Medicine
https://www.readbyqxmd.com/read/28152356/cardiovascular-disease-in-patients-with-schizophrenia
#17
Leonard Kritharides, Vincent Chow, Tim Jr Lambert
Patients with schizophrenia die on average 25 years earlier than the general population, and this gap appears to be increasing. Most of the excess mortality is due to premature cardiovascular deaths rather than suicide. Many psychotropic agents are orexigenic and can increase weight and promote dyslipidaemia. Traditional cardiac risk factors are undertreated among patients with schizophrenia, and they are less likely to receive cardiac revascularisation than those without a mental illness. Clozapine is an atypical antipsychotic medication effective for treatment of refractory schizophrenia, but is associated with the risk of myocarditis and cardiomyopathy...
February 6, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28150806/dyslipidaemia-small-triumph-for-fenofibrate-therapy-in-dyslipidaemia
#18
Robert S Rosenson
No abstract text is available yet for this article.
February 2, 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/28149009/serum-lipid-alterations-in-early-rheumatoid-arthritis-patients-on-disease-modifying-anti-rheumatoid-therapy
#19
Sana Parveen, Rachel Jacob, Liza Rajasekhar, C Srinivasa, Iyyapu Krishna Mohan
Dyslipidaemia is a major CVD risk factor in the general population. Current evidence suggests that lipid metabolism is altered in RA due to inflammation, and that use of anti-inflammatory therapy may reverse some of these changes. The objective of our study is to compare the effect of treatment with DMARD on lipid fractions after 6 months of therapy. Forty patients who met the American College of Rheumatology, ACR/EULAR criteria for rheumatoid arthritis, with disease duration of less than 1 year and no prior treatment were included in the study...
March 2017: Indian Journal of Clinical Biochemistry: IJCB
https://www.readbyqxmd.com/read/28144253/pola-cfpip-pcs-guidelines-for-the-management-of-dyslipidaemias-for-family-physicians-2016
#20
Maciej Banach, Piotr Jankowski, Jacek Jóźwiak, Barbara Cybulska, Adam Windak, Tomasz Guzik, Artur Mamcarz, Marlena Broncel, Tomasz Tomasik, Jacek Rysz, Agnieszka Jankowska-Zduńczyk, Piotr Hoffman, Agnieszka Mastalerz-Migas
No abstract text is available yet for this article.
February 1, 2017: Archives of Medical Science: AMS
keyword
keyword
71061
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"